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Imaging in clinical trials is used to evaluate subject eligibility, and/or efﬁcacy of intervention, supporting
decision making in drug development by ascertaining treatment effects on joint structure. This review
focusses on imaging of bone and cartilage in clinical trials of (knee) osteoarthritis. We narratively review
the full-text literature on imaging of bone and cartilage, adding primary experience in the imple-
mentation of imaging methods in clinical trials. Aims and constraints of applying imaging in clinical trials
are outlined. The speciﬁc uses of semi-quantitative and quantitative imaging biomarkers of bone and
cartilage in osteoarthritis trials are summarized, focusing on radiography and magnetic resonance im-
aging (MRI). Studies having compared both imaging methodologies directly and those having established
a relationship between imaging biomarkers and clinical outcomes are highlighted. To make this review
of practical use, recommendations are provided as to which imaging protocols are ideal for capturing
speciﬁc aspects of bone and cartilage tissue, and pitfalls in their usage are highlighted. Further, the
longitudinal sensitivity to change, of different imaging methods is reported for various patient strata.
From these power calculations can be accomplished, provided the strength of the treatment effect is
known. In conclusion, current imaging methodologies provide powerful tools for scoring and measuring
morphological and compositional aspects of most articular tissues, capturing longitudinal change with
reasonable to excellent sensitivity. When employed properly, imaging has tremendous potential for
ascertaining treatment effects on various joint structures, potentially over shorter time scales than
required for demonstrating effects on clinical outcomes.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Clinical trials are designed to objectively test the effect of an
intervention on the disease process. In osteoarthritis (OA), clinical
outcomes (pain and function) are unable to elucidate whether the
effect of intervention is purely symptomatic or modifying the dis-
ease process at a structural, joint tissue level. While molecularto: F. Eckstein, Institute of
21, A5020 Salzburg, Austria.
9.
in).
ternational. Published by Elsevier Lmarkers from serum or urine may identify processes of tissue for-
mation and degradation, they represent all body tissue turn-over.
Evaluating interventions at speciﬁc joints and tissues thus has to
rely on imaging.
Imagingmeasures should be accurate, precise (reliable), speciﬁc,
sensitive to longitudinal change, and acceptable to regulatory
agencies. Current regulatory guidance for approval of disease
modifying OA drugs (DMOADs) recommends that reduction of
structural pathology in joint tissue should be accompanied by
beneﬁts in clinical outcomes. Studies relating imaging “bio-
markers” to clinical outcomes therefore are of particular interest.
All synovial joint tissues are known contribute to the development
or progression of OA. However, articular cartilage warrants almosttd. All rights reserved.
F. Eckstein et al. / Osteoarthritis and Cartilage 22 (2014) 1516e1532 1517frictionless transmission of dynamic forces in joints, and when
cartilage is lost and subchondral bone exposed, joint function de-
clines. This review therefore focuses on imaging of cartilage and
bone tissue in clinical trials.
The authors searched literature from Pubmed up to January 1st,
2014. Studies were prioritized for inclusion, when critically evalu-
ating reliability, sensitivity to change, association with clinical
outcomes, and efﬁcacy in evaluating treatment effects for certain
imaging methods, or when comparing different methodologies
directly. Primary experience in implementing imaging methods
was added, with the authors having a variety of backgrounds,
including radiology, anatomy, rheumatology, medical image data
analysis, work in a clinical research organization, or in the phar-
maceutical industry. Recommendations are provided as to which
imaging protocols are ideal for capturing speciﬁc aspects and im-
aging metrics of speciﬁc tissues (Table I), and pitfalls in their usage
are outlined.Where available, sensitivity to changewill be reported
as “standardized response mean” (SRM) (Table II). Given the het-
erogeneity of study populations and observation periods, no
attempt was made to derive summary measures across studies, or
measures of consistency and risk bias. Rather, results were tabu-
lated covering a wide range of conditions, to provide estimates of
sensitivity to change for a variety of selection criteria and design
parameters (Table II).
Primary aims and constraints of clinical trials
Medical imaging is used for screening, diagnosis/prognosis,
evaluating the natural history of disease, or monitoring therapy.
Imaging requirements for safety evaluations will not be considered
here, given space limitations. In efﬁcacy evaluation, imaging is used
for monitoring natural history (placebo) vs therapy. The metrics to
be satisﬁed by imaging parameters for clinical trials have been
described1. A key metric is “precision” (also “reproducibility” or
“reliability”), which refers to the degree to which repeated
(testeretest) measurements show the same result under un-
changed conditions. Currently only radiographs are accepted for
DMOAD Phase III trials by regulatory agencies, but there is new
guidance that may provide a pathway for the utilization of mag-
netic resonance imaging (MRI) (http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM230597.pdf), whereas in cartilage repair MRI already has been
accepted as an endpoint.
The decision of which imaging technique to use in a clinical trial
depends on the mechanism of DMOAD action. RadiographicTable I
MRI acquisition techniques supporting different imaging measures used in clinical trials
Imaging measure Image acquisition required Recommended res
SlTh In pl
Cartilage lesion scoring IW F/TSE 3 mm 0.5
BML scoring IW F/TSE fs 3 mm 0.5
Cartilage thickness/volume FLASH/SPGR/FFE/WATSc fs/we 1.5 mm 0.3
DESS we 1.5 mm 0.3
Cartilage composition
T2 MESE (6e7 echos) 3 mm 0.7
T2/diffusion DESS 1.5 mm 0.3
T1rho 500 Hz spin lock 3 mm 0.7
dGEMRIC T1-mapping 3 mm 0.7
Sodium PR or cones 4 mm 1.2
CEST Multiple RF pulses 3 mm 0.7
Ultra-short TE PR or cones 3 mm 0.7
IW F/TSE fs ¼ intermediate weighted fast or turbo spin echo sequence with fat suppre
relaxation time, T1rho ¼ measurement of the spin-lattice relaxation time, iv ¼ intraven
reconstruction.assessment of femorotibial “joint space width (JSW) or narrowing”
(JSN) represents a composite measure, because more than one
tissue is present between femoral and tibial subchondral bone. MRI
is more speciﬁc to a variety of articular tissues, but careful
considerationmust bemade as towhich joint region and tissue is to
be evaluated, and which speciﬁc scoring or measuring methods are
to be applied. For MRI of the knee, magnets with 1.5 T and
dedicated knee coils are highly preferable. Subtle differences have
been reported between quadrature and phased array coils2,3, the
latter providing greater signal. Signal homogeneity, high contrast-
to-noise, minimization of technical artifacts, and full anatomical
coverage of structures of interest are crucial. Patient positioning,
image orientation, and spatial resolution must be matched to the
speciﬁc goals and measurement method. Compromises have to be
achieved regarding acquisition time, patient comfort, cost, image
quality, resolution, and number/types of imaging protocols ob-
tained supporting various imaging measures (Table I). Monthly
phantom measurements and quality assurance procedures in the
Osteoarthritis Initiative (OAI) have revealed that geometric MRI
measures were consistent between different sites, and that geo-
metric measures and MRI relaxation times (T2) were stable over
now up to 8 years follow-up4. Whichever imaging and scoring/
measurement method used, central review of the images by expert
readers is highly preferable5. These have to agree on the speciﬁc
approach before evaluating images, to ensure consistent applica-
tion of scoring or measurement technology. Further, intra- (and
inter-) reader variability should be tested within clinical trials, to
ensure consistency and precision under speciﬁc conditions. In
cross-sectional studies, the inter-observer error must be substan-
tially lower than the between-subject variability to ensure robust
differentiation of study participants. In longitudinal studies, base-
line and follow-images should always be evaluated by the same
reader, because intra-observer errors are generally smaller than
inter-observer errors6. Preferably, also, the intra-observer error
should be small in relation to the “effect” that is being measured to
avoid large sample sizes7.
Use of radiography in OA clinical trials
Radiographic acquisition techniques and quality control
Radiographs can be used for establishing disease severity during
screening to determine patient eligibility, and for evaluating dis-
ease progression with and without DMOAD treatment. While his-
torically diagnosis and disease severity have been established onol. Key validation papers Other recommendations
ane
mm Refs. 56,57 2e3 planes and TE < 45 ms required
mm Refs. 58,59 2e3 planes and fs required
5 mm Refs. 60e62 TE < 10 ms
5 mm Refs. 65,66 With 0.7 mm every second slice sufﬁcient
mm Refs. 2,117,120 Eliminate shortest (10 ms) TE from ﬁt
5 mm Refs. 118,119 Potentially simultaneous thickness analysis
mm Refs. 120,122,123 Spin lock followed by SE or GRE readout
mm Refs. 116,124,125 Requires iv Gd injection 90 min before
mm Ref. 128 Requires specialized coil and high ﬁeld
mm Refs. 129,130 Requires high ﬁeld (3 or 7 T)
mm Ref. 131 TE < 5 ms (available in 2D or 3D)
ssion, SE ¼ spin echo, GRE ¼ gradient echo, T2 ¼ measurement of the spinespin
ous, Gd ¼ gadolinium, SlTh ¼ slice thickness, resol. ¼ resolution, PR ¼ projection-
Table II
Sensitivity to change for different radiographic and MRI measures of progression, depending on speciﬁc inclusion criteria
Author Study Rx/MRI technique n ¼ X Inclusion speciﬁcs Measure Time Main ﬁnding
(MC ± SD)
Sensitivity to change
(SRM)
Radiography only (JSW change)
Brandt et al.46 Doxycycline
(placebo group)
Semiﬂexed Rx
(with ﬂuoro)
180 KLG 2/3 [index knee] mJSW 16 M 0.24 ± 0.54 mm 0.44
30 M 0.45 ± 0.70 mm 0.64
KLG 0/1 [contra-lateral knee] mJSW 16 M 0.23 ± 0.59 mm 0.39
30 M 0.41 ± 0.67 mm 0.61
Hellio et al.17 SD-6010
(placebo groups)
Mod. Lyon-Schuss 222 KLG 2*/3 mJSW 1 Y 0.13 ± 0.36 mm 0.36
264 mJSW 2 Y 0.22 ± 0.45 mm 0.49
Oak et al.35 OAI FFR 942 KLG 2e4 mJSW 4 Y 0.54 ± 0.94 mm 0.57
Reginster et al.47 SEKOIA
(placebo groups)
FFR 472 KLG 2/3 mJSW 3 Y 0.37 ± 0.59 mm 0.63
MRI only (cartilage thickness or cartilage volume change)
Cicuttini et al.92 e Cor MPR 117 WOMAC knee pain
and osteophytes
MF 1.9 Y 0.15 ± 0.30 ml/year 0.50
GRASS MT 0.10 ± 0.25 ml/year 0.40
LF 0.15 ± 0.22 ml/year 0.68
LT 0.12 ± 0.16 ml/year 0.75
Raynauld et al.93 e Sag FISP 32 KLG 2/3 MFTC 1 Y 4.2 ± 7.5 % 0.56
2 Y 7.6 ± 8.6 % 0.88
Wluka et al.94 e Sag GRASS 78 Pain þ osteophytes MT 4.5 Y 63 ± 78 mm3/year 0.81
LT 72 ± 73 mm3/year 0.99
Eckstein et al.96 MAK Cor FLASH 74 Neutral MFTC 2.3 Y 1.4 ± 2.8%/year - 0.50
LFTC 1.0 ± 2.4%/year - 0.42
57 Varus MFTC 2.6 ± 4.2%/year - 0.62
LFTC 0.7 ± 2.1%/year - 0.34
43 Valgus MFTC 0.4 ± 2.1%/year - 0.19
LFTC 2.4 ± 3.9%/year - 0.61
Eckstein et al.99 OAI Cor FLASH 112 NEC MFTC 1 Y 0.002 ± 0.100 mm 0.02
310 KLG 2# MFTC 0.013 ± 0.100 mm 0.13
300 KLG 3 MFTC 0.040 ± 0.129 mm 0.31
109 KLG 4 MFTC 0.055 ± 0.145 mm 0.38
Eckstein et al.102 OAI Cor FLASH 255 x no pain MFTC 1 Y 0.016 ± 0.085 mm 0.19
117 x infreq. pain MFTC 0.021 ± 0.098 mm 0.21
111 x freq. pain MFTC 0.045 ± 0.148 mm 0.30
Eckstein et al.7 OAI Sag DESS 216 KLG 2# MFTC 1 Y 0.017 ± 0.142 mm 0.12
cMFTC 1 Y 0.043 ± 0.205 mm 0.21
2 Y 0.087 ± 0.249 mm 0.35
3 Y 0.155 ± 0.337 mm 0.46
4 Y 0.198 ± 0.388 mm 0.51
KLG 3 MFTC 1 Y 0.086 ± 0.169 mm 0.51
cMFTC 1 Y 0.163 ± 0.267 mm 0.61
2 Y 0.256 ± 0.376 mm 0.68
3 Y 0.334 ± 0.445 mm 0.75
4 Y 0.498 ± 0.572 mm 0.87
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Pelletier et al.79 SEKOIA
(placebo only)
FISP/SPGR 112 KLG 2/3 MT 3 Y 7.2 ± 7.7% 0.94
MF 8.5 ± 4.5% 1.89
Wirth et al.101 OAI Cor FLASH & Sag
DESS
158 KLG 2# MFTC 1 Y 0.002 ± 0.087 mm 0.02
270 Med JSN1 MFTC 0.029 ± 0.129 mm - 0.22
280 Med JSN2 MFTC 0.091 ± 0.171 mm 0.53
39 Med JSN3 MFTC 0.092 ± 0.146 mm 0.63
158 KLG 2# LFTC 0.008 ± 0.084 mm 0.09
65 Lat JSN1 LFTC 0.064 ± 0.132 mm 0.48
90 Lat JSN2 LFTC 0.092 ± 0.193 mm 0.48
20 Lat JSN3 LFTC 0.085 ± 0.158 mm 0.53
Martel-Pelletier et al.107 OAI (Glu/CS) (groups
without Glu/CS)
Sag DESS KLG 0e4
210 NSAIDS MFTC 1 Y 1.9 ± 3.6% 0.53
2 Y 3.0 ± 4.6% 0.65
NSAIDS LFTC 1 Y 1.5 ± 3.8% 0.39
2 Y 2.5 ± 4.5% 0.56
187 þNSAIDS MFTC 1 Y 2.4 ± 4.7% 0.51
2 Y 4.0 ± 6.1% 0.66
þNSAIDS LFTC 1 Y 2.3 ± 4.1% 0.56
2 Y 3.9 ± 5.0% 0.78
Radiography (JSW) and MRI (cartilage thickness or volume change) in the same sample
Raynauld et al.95 e Semiﬂexed Rx
(with ﬂouro) Sag
FISP
107 Symptoms mJSW 1 Y Not reported
Osteophytes 2 Y 0.16 ± 0.49 mm 0.33
MFTC 1 Y 256 ± 211 mm3 1.21
(vol.) 2 Y 405 ± 320 mm3 1.27
Raynauld et al.112 Licofelone (Naproxen
[control] group)
3D FISP/SPGR <154 Pain þ mJSW 1 Y 0.22 ± 0.47 mm 0.47
KLG 2/3 MFTC 1 Y 299 ± 183 mm3 1.64
LFTC 1 Y 244 ± 168 mm3 1.45
mJSW 2 Y 0.38 ± 0.54 mm 0.70
MFTC 2 Y 485 ± 237 mm3 2.04
LFTC 2 Y 369 ± 161 mm3 2.28
Le Graverand et al.148 A9001140 Lyon-Schuss 27 KLG 2 mJSW 2 Y 0.07 ± 0.22 mm 0.32
FFR mJSW (annualized) þ0.03 ± 0.64 mm þ0.11
Cor FLASH MFTC 0.01 ± 0.03 mm 0.03
cMFTC 0.01 ± 0.07 mm 0.15
Lyon-Schuss 28 KLG 3 mJSW 2 Y 0.22 ± 0.35 mm 0.62
FFR mJSW (annualized) 0.07 ± 0.35 mm 0.20
Cor FLASH MFTC 0.05 ± 0.11 mm 0.44
cMFTC 0.09 ± 0.19 mm 0.48
Duryea et al.30 OAI Sag DESS 116 KLG 2/3 MT 1 Y þ0.01 ± 0.11 mm3 þ0.02
LT 0.02 ± 0.09 mm3 0.26
MF 0.04 ± 0.11 mm3 0.42
LF 0.01 ± 0.08 mm3 0.09
FFR mJSW 0.12 ± 0.64 mm 0.18
JSW (X ¼ 0.25) 0.21 ± 0.60 mm 0.34
JSW (X ¼ 0.70) 0.20 ± 0.73 mm 0.27
(continued on next page)
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Table II (continued )
Author Study Rx/MRI technique n ¼ X Inclusion speciﬁcs Measure Time Main ﬁnding
(MC ± SD)
Sensitivity to change
(SRM)
Wirth et al.31 OAI Cor FLASH 445 KLG 2e4 MFTC 1 Y 1.1 ± 3.9% 0.28
cMFTC 1.6 ± 5.0 % 0.32
FFR mJSW 2.3 ± 15.2 % 0.15
JSW (X ¼ 0.250) 2.2 ± 10.3 % 0.22
Sag DESS 522 KLG 2e4 MFTC 2 Y 2.6 ± 6.1 % 0.43
cMFTC 4.2 ± 8.2% 0.51
FFR mJSW 5.4 ± 17.5% 0.31
JSW (X ¼ 0.225) 5.3 ± 12.1% 0.44
Cromer et al.147 LEGS Semiﬂexed Rx 23 Chronic pain  1 mm
mJSW
mJSW 0.10 ± 0.22 mm 0.46
Sag FLASH MT 0.04 ± 0.07 mm 0.56
cMF 0.09 ± 0.15 mm 0.59
Cartilage composition measurement with MRI
McAlindon133 Placebo group dGEMRIC index 13 Deﬁnite osteophytes,
mJSW > 3 mm
MT 1 Y 2.4 ± 64.4 0.04
Sag IR fast SPGR cMF 14.3 ± 52.1 0.28
pMF 2.2 ± 55.4 0.05
LT 17.3 ± 55.3 0.31
cLF 15.2 ± 43.7 0.35
pLF 40.3 ± 88.3 0.46
T2 11 Deﬁnite osteophytes,
mJSW > 3 mm
MT 1.0 ms Median, SD
not reported
Sag fast SE FS
dual echo
cMF 1.0 ms
pMF 2.0 ms
LT 1.0 ms
cLF 0.0 ms
pLF 0.0 ms
Anandacoomarasamy
et al.132
Cartilage thickness 78 BMI > 30 kg/m2
(z32% ACR OA)
MT 1 Y 0.02 ± 0.1 mm 0.20
Sag FISP cMF 0.004 ± 0.2 mm 0.02
LT 0.006 ± 0.1 mm 0.06
cLF 0.07 ± 0.1 mm 0.70
dGEMRIC index
(Sag T1Gd maps)
54 BMI > 30 kg/m2
(z26% ACR OA)
MT 23 ± 126 0.18
cMF 2 ± 123 0.02
LT 23 ± 135 0.17
cLF 23 ± 107 0.22
Studies published on responsiveness of radiographic22 and MRI measures75 prior to April 2009 have been systematically summarized in the two above articles. Therefore, only few studies published before 2009 were added to
the above table as a reference, with the focus being on studies published 2009e2013. The pooled SRM for radiographic JSW change reported by Reichmann et al.22 was 0.33 (95% CI: 0.26, 0.41) (43 estimates). Estimates derived
from studies with <1 Y and 1e2 Y follow-up had similar responsiveness (0.24 and 0.25 respectively). Estimates from studies with >2 Y follow-up had a pooled SRM of 0.57 (95% CI: 0.39, 0.75). The pooled SRM for cartilage
thickness reported by Hunter et al.75 for quantitative measures of cartilage morphometry (study durations 6 M to 2 Y) was0.86 (95% CI:1.26 to 0.46) for the medial femorotibial joint (31 estimates),1.01 (95% CI:2.04 to
0.02) for the lateral femorotibial joint (14 estimates), and 0.63 (95% CI: 0.90 to 0.37) for the patella (13 estimates). The pooled SRM for semi-quantitative measures of cartilage (increase in lesion scores) was 0.55 (95% CI:
0.47e0.64) for the medial femorotibial joint (three estimates), 0.37 (95% CI: 0.18e0.57) for lateral femorotibial joint (three estimates), and 0.29 (95% CI: 0.03e0.56) for the patella (two estimates). The pooled SRM for semi-
quantitative measures of BMLs (six estimates) was 0.43 (95% CI: 0.17 to 1.03).
Abbreviations: MC¼mean change; SD¼ standard deviation of change; SRM¼ standardized responsemean¼MC/SD. All changes in radiographic (Rx)medial JSW given inmm.MRI-based cartilage changes given inmm (or %) for
change in cartilage thickness or inml/mm3 for changes in cartilage volume (vol); JSW(X)¼ JSWmeasurement at a ﬁxed location in themedial (X¼ 0.15e0.3) or lateral (X¼ 0.7e0.9) compartment; MT¼medial tibia; MF¼medial
femur; cMF¼ central, weight-baring part of the medial femur; pMF¼ posterior part of the medial femur; MFTC¼medial femorotibial compartment ¼MTþ cMF; cMFTC¼ central part of the MFTC. LT¼ lateral tibia; LF¼ lateral
femur; cLF ¼ central, weight-baring part of the lateral femur; pLF ¼ posterior part of the lateral femur; LFTC ¼ lateral femorotibial compartment ¼ LT þ cLF; mod ¼modiﬁed; ﬂuoro ¼ ﬂuoroscopy; 1 Y/2 Y/3 Y/4 Y ¼ 1-/2-/3-/4-
year follow-up; 16 M/30 M¼ 16-month/30-month follow-up; 48W¼ 48-week follow-up; Cor¼ coronal; Sag ¼ sagittal; MPR¼multi-planar reconstruction; GRASS ¼ T1-weighted fat-suppressed 3-dimensional gradient recall
acquisition in the steady state; FFR ¼ ﬁxed ﬂexion radiography; IR ¼ inversion recovery; FISP ¼ fast imaging with steady state precession; SE ¼ spin echo; T2 ¼ spinespin relaxation time; T1Gd ¼ gadolinium enhanced T1-
weighted MRI; KLG 2* ¼ knees with deﬁnite osteophytes and WITH radiographic JSN; ref ¼ reference; KLG 2# ¼ knees with deﬁnite osteophytes WITHOUT radiographic JSN; x mixture of KLG 2# and KLG 3 knees; ACR
OA ¼ criteria of the American College of Rheumatology for osteoarthritis; WOMAC ¼ Western Ontario and McMaster Universities Arthritis Index; NEC ¼ non-exposed controls.
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Fig. 1. Radiography [(D)e(I) are from the OAI]. (A) Leg positioning and direction of X-ray tube, perpendicular to the medial tibial plateau. (B) Layout of the patient positioning device
and bucky. (C) Properly acquired X-ray: the tibial spines are centered within the femoral condyle notch. Adequate spacing between the tibia and ﬁbula indicates that there is no
internal or external rotation. The knee joint space is centered from top-to-bottom and left-to-right on the ﬁlm, and at least ﬁve beads above and below knee joint space. The outer
margins of the femur and tibia are clearly visible. The exposure is optimized for visualizing bone details. Both rows of calibration markers positioning unit are visible. (D) IMD of
second radiograph (ﬁrst was 100) 8 mm still showing sub-optimal IMD. (E) Automated measurement of the minimum (JSW) between the femoral and tibial margins. (F) Coordinate
system for ﬁxed location JSW in medial (X ¼ 0.15e0.3) and lateral (X ¼ 0.7e0.9) compartment. (G) X-ray of a knee classiﬁed as KLG2, deﬁnite osteophyte and OARSI medial JSN
grade0. (H) X-ray of a knee classiﬁed as KLG2, deﬁnite osteophyte and OARSI medial JSN grade1. (I) X-ray of a knee classiﬁed as KLG3, deﬁnite osteophyte and OARSI medial JSN
grade2.
F. Eckstein et al. / Osteoarthritis and Cartilage 22 (2014) 1516e1532 1521conventional extended radiographs (bilateral weight-bearing
antero-posterior view of both knees in full extension) differences
in grading have been observed between radiographic protocols8.
Therefore use of the same protocol for evaluating eligibility and
progression is recommended for clinical trials. Accurate and precise
evaluation of disease progression requires acquisition of a repro-
ducible image of radiographic JSW, and adherence to standards of
knee positioning9. Several protocols have been developed to
address the characteristics of knee joint anatomy. Common to all is
a standard for both weight-bearing and knee ﬂexion; weight-
bearing acquisition ensures similar cartilage compression/hydra-
tion and joint positioning between examinations. Loaded joints
exhibit signiﬁcantly smaller and more medially located minimum
medial joint space width (mJSW) than unloaded joints10. Knee
ﬂexion provides contact between the tibia and the central/posterior
aspect of the femoral condyle where OA-related cartilage damage
was reported to be prominent11. The ﬁrst standardized positioning
protocol was the semiﬂexed antero-posterior view: ﬂuoroscopy
was used to guide knee ﬂexion and rotation and to achieve repro-
ducible and parallel alignment of the medial tibial plateau relative
to a horizontal X-ray beam12. This alignment warrants a morereproducible measurement of JSW compared to extended
views12,13. Subsequently, the posterioreanterior Lyon-Schuss view
was developed, using a co-planar alignment of the hip, patella, and
great toe to achieve greater degrees of ﬁxed knee ﬂexion in repeat
examinations14. However, due to increased radiation exposure and
decreased ﬂuoroscopic use, alternative protocols were developed
to facilitate use in clinical trials, including ﬁxed ﬂexion13 and
metatarsophalangeal protocols15. Positioning devices9 permit
standardization of knee ﬂexion, foot rotation and the inclusion of
markers in the ﬁeld of view permit correction for magniﬁcation
caused by beam divergence and ﬁlm focus distance. A single knee
(rather than both) should be imaged at a time, to ensure minimal
beam divergence. All standardized radiographic protocols offer
greater precision than the conventional extended knee radiograph.
However, among the rare head-to-head comparisons of alternative
positioning protocols, greater sensitivity to change has been re-
ported for ﬂuoroscopy-assisted than for non-ﬂuoroscopic pro-
tocols13,16. Since parallel radio-anatomic alignment of the medial
tibial plateau with the X-ray beam signiﬁcantly improves sensi-
tivity to change, multiple radiographic acquisitions per knee have
been used alternatively, to ensure optimal acquisition without
F. Eckstein et al. / Osteoarthritis and Cartilage 22 (2014) 1516e15321522ﬂuoroscopy17. Amaximum1.5mm inter-margin distance (IMD), i.e.,
the projected difference between the anterior and posterior rims of
the medial tibial plateau, was identiﬁed to be key quality control
parameter18. However, some studies have even recommended de-
viations to be kept below 1.0 mm12,19. Detailed methodology for
acquisition and quality control of the modiﬁed Lyon-Schuss was
recently reported from a large DMOAD trial17,20.Semi-quantitative grading of radiographs
OA severity can be graded semi-quantitatively, the Kellgren and
Lawrence grade (KLG)21 being the oldest and most commonly used
system. It permits demographic characterization and stratiﬁcation
of study participants22, and can be used to deﬁne eligibility for
clinical trials. Radiographic OA is deﬁned as KLG  2 (deﬁnite
osteophytes). However, limitations are such that KLG 2may include
knees with and without JSN17, and that KLG 3 includes various
degree of JSN23; hence each KLG encompasses a wide spectrum of
joint pathology (Fig. 1). JSN is not caused by cartilage loss alone, but
also by meniscal extrusion, independently of cartilage status24.
Several modiﬁcations of KLG system exist25, some of which pro-
posed to improve sensitivity to change26. Modiﬁcations of existing
systems25 should be clearly reported to be able to compare disease
burden in populations or drug efﬁcacy across disease severities. TheFig. 2. Semi-quantitative scoring of cartilage and BMLs. The images show cartilage damage
discrete retro-patellar cartilage damage (white arrow) and small cystic subchondral BML
suppressed (IW-TSE fs) image showing the true extent of focal cartilage defect due to an
subchondral BML (arrowheads) in addition to the small cystic lesion depicted in (A). (C) S
intensity (arrow). It remains unclear if this ﬁnding represents intra-cartilaginous signal cha
cannot be unequivocally determined. (D) Coronal intermediate-weighted MRI without fs s
subchondral plate (arrow).Osteoarthritis Research Society International (OARSI) atlas27 grades
osteophytes and JSN separately in medial and lateral femorotibial
compartments (Fig. 1). Using a between-knee comparisonwithMRI
in subjects with unilateral JSN, the amount of cartilage loss per JSN
grade was estimated, and was found to vary substantially between
subjects23. JSN grades were found to be more strongly related to
pain than osteophytes28. Disease progression can be deﬁned as an
increase in KLG, osteophyte, or JSN grade, with greater inter-
observer variability for KLG and osteophytes than for JSN5. Given
these limitations, there is an ongoing debate regarding the suit-
ability of radiographic measures to deﬁne eligibility criteria and for
outcome assessment of clinical trials29.Quantitative measurement of radiographic JSW
Measurement of JSW by manual and semi-automated methods
has been reviewed previously9 and a meta-analysis of its reliability
and sensitivity to change has been presented22. Today, JSW can be
measured almost fully automatically using computer-delineation of
femoral and tibial margins30. As stated above, accurate measure-
ment depends on the alignment of the medial tibial plateau with
the X-ray beam19. JSW may be deﬁned as the minimum distance
between the opposing bones of the joint (mJSW) or as the distance
at speciﬁc locations with respect to deﬁned anatomicalusing 3 T MRIs from the Osteoarthritis Initiative. (A) Sagittal DESS sequence showing
(arrowhead). (B) Corresponding sagittal intermediate-weighted turbo spin echo fat-
arthrographic effect of joint ﬂuid (black arrow) and also depicting a large ill-deﬁned
agittal IW TSE fs MRI of a different knee showing subtle focal intra-chondral hyper-
nge of unknown signiﬁcance or a true surface defect. Furthermore depth of the lesion
howing that the lesion in (C) represents a full thickness focal defect that reaches the
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Fig. 3. Quantitative analysis of articular cartilage from MRI. (A) Sagittal FLASH with water excitation showing different regions of interest in the knee:P ¼ Patella, TrF ¼ femoral
trochlea, LT ¼ lateral tibia, cLF ¼ central (weight-bearing) lateral femur, pLF ¼ posterior (weight-bearing) lateral femur (LT þ cLF ¼ lateral femorotibial compartment ¼ LFTC). (B)
Coronal FLASH with water excitation. The segmentation of the total area of subchondral bone (tAB) is shown in dark green, the area of the cartilage surface (AC) in magenta. The AC
of the MT only partially covers the tAB, separating it into a cartilage-covered part (cAB) and a denuded part (dAB). (C) 3D reconstruction of the knee showing cartilage thickness
distribution in the tibia in colors, the TrF cartilage in gray, and the femoral bone using grid lines. (D) Sagittal DESS showing segmentation of the medial femur (MF) and tibia (MT).
(E) Coronal multiplanar reconstruction of the DESS showing segmentation of the MT and central (weight-bearing) part of the medial femur (cMF); MT þ cMF ¼medial femorotibial
compartment ¼ MFTC. (F) Axial multiplanar reconstruction of the DESS without segmentation.
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tivity to change (Table II) in knees without deﬁnite radiographic OA
(KLG  1), but location-speciﬁc JSW measures were more respon-
sive in knees with OA (KLG  2)30,31. Being a continuous outcome,
JSW loss generally is reported as the mean [and standard deviation
(SD)] difference between baseline and follow-up. However, efforts
have been made to deﬁne cut-offs that separate “progression” from
normal measurement variability32. The disadvantage of this
approach is a potential loss of information, but its strength lies in
the reduction of measurement noise and in the easier (statistical)handling of dichotomized outcomes of progressors vs non-pro-
gressors32. Albeit various thresholds of JSW loss have been sug-
gested, no consensus currently exists as to which one accurately
deﬁnes structural progression32. Evidence exists that JSW loss is
associated with the risk of subsequent knee replacement33,34, an
important and economically relevant clinical outcome. Also, JSW
loss was associated with concurrent worsening of pain, function
and quality of life35. Further, quantitative JSW has been used in a
large number of studies that have explored risk factors for knee OA
progression36; however, methodological challenges (e.g., collider
Fig. 4. Compositional cartilage imaging. Compositional maps for a healthy volunteer
are shown as overlays on gray scale morphologic images. (A) Spinespin relaxation
time (T2) map with higher values (red) showing increased T2 (ms). (B) Relaxation time
in a rotating ﬁeld (T1rho) map with higher values (red) showing increased T1rho (ms).
(C) Sodium MRI map with heat scale showing signal intensity that reﬂects cartilage
sodium concentration. T2 is sensitive to collagen matrix composition and organiza-
tional changes. T1rho and sodium measures have been shown to be sensitive to
changes in glycosaminoglycan content. These measures may be useful in detection and
characterization of early disease before tissue loss occurs.
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interpretation37. Yet, varus/valgus mal-alignment of the knee has
been consistently shown to be a strong predictor of JSW loss and
functional decline38, including the medial and lateral compart-
ment39. However, the effect of mal-alignment may be modiﬁed by
variability in body weight40 and baseline KLG41. Knees with inci-
dent radiographic disease (KLG  2) were at higher risk of subse-
quent progression than those that were in a stable radiographic
state42. Being an accepted structural outcome for Phase III clinical
trials, JSW loss has been used in a series of DMOAD intervention
studies20,43e47. Clinical trials aiming at measuring JSW loss in the
medial compartment often have included knees with at least some
medial JSN, to ensure sufﬁcient progression in the placebo group17.
However, with some DMOADs, treatment effects may only be
demonstrable relatively early in the disease, with some trials hav-
ing shown efﬁcacy in reducing JSW loss in knees with mild but not
in those with advanced radiographic OA20,43,46. Along the same
lines, in some trials effects were seen over 1, but lost over 2
years20,44,45. Also, clinical trials often have excluded severely mal-
aligned knees, because extensive biomechanical challenge may
negate potential beneﬁts of DMOAD intervention48. Those with
valgus may develop lateral OA, potentially associated with medial
pseudo-widening of medial JSW measurements20.
Radiographic analysis techniques and alignment measures
Radiographs can be used further to measure the femorotibial
knee alignment (varus/valgus). The most widely accepted measure
is the hipekneeeankle angle (HKA; i.e., mechanical axis), requiring
full-length lower-limb radiographs49. The femur-tibia angle (FTA;
anatomical axis) can be determined from conventional knee ra-
diographs, but has a deﬁned offset (approx. 4) and limited corre-
lationwith the HKA50,51. Yet, FTAwas used in a recent clinical trial20
and was reported to be equally predictive of JSW loss as HKA51.
Measures of trabecular texture, such as fractal signature analysis
(FSA) may provide estimates of bone density and microstructural
change associated with OA and its therapy52. FSA was found pre-
dictive of structural progression by radiography and MRI53.
Use of MRI in clinical trials
MRI acquisition techniques
The OARSI/Outcome Measures in Rheumatoid Arthritis Clinical
Trials (OMERACT) consensus review summarized the MRI se-
quences that should be used for each OA feature of OA54. A protocol
using a minimum number of sequences and permitting whole-
organ assessment of the majority of articular features should
comprise “ﬂuid-sensitive” (proton density-, intermediate- or T2-
weighted) fast or turbo spin echo sequences55e59 (Fig. 2). These
must be acquired in 2 orthogonal planes to avoid that partial
volume effects at the joint margins of sagittal images are mis-
interpreted as bone marrow lesion (BML), if not conﬁrmed in the
coronal plane; further volume estimates from one plane are unre-
liable. Imaging cartilage with heavy T2 weighting prevents differ-
entiation of the deep cartilage from the subchondral plate, and
therefore echo times (TEs) <45 ms (proton density- or
intermediated-weighted sequences) are recommended. Non-fat
suppressed pulse sequences were shown to be precise and to
agree with arthroscopic evaluation, provided that adequate spatial
resolution, short inter-echo spacing, and awide receiver bandwidth
were utilized56. However, fat suppression (fs) is required if BMLs
are to be assessed from the same images. Some investigators have
used gradient-echo type sequences [e.g., double echo steady state
(DESS, Fig. 2), fast low-angle shot (FLASH), or spoiled gradientrecalled acquisition in steady state (SPGR)] for assessing BMLs and
focal cartilage defects, but several studies have shown that
gradient-echo sequences are insensitive to these features and are
not suited for such purpose57e59.
The imaging sequences required for quantitative measurement
of cartilage morphology (i.e., volume, thickness) differ from those
used for semi-quantitative grading in that spatial resolution is more
critical, and the cartilage surface and bone interface need to be
F. Eckstein et al. / Osteoarthritis and Cartilage 22 (2014) 1516e1532 1525delineated accurately (Fig. 3). Adequate contrast and adequate
spatial resolution (preferably 1.5 mm slice thickness and
0.35 mm in-plane) can be obtained at 1.5 T ﬁeld strength, using
T1-weighted FLASH (Siemens), SPGR (General Electric), or fast ﬁeld
echo (FFE) or water selective cartilage scan (WATSc) (Philips) im-
ages with fs6 (Table I). Shorter acquisition times can be obtained by
using selective water excitation (we) (Fig. 3) and these protocols
have been validated60 and were shown to be stable over time in
multicenter trials61. Comparisons have been made between coils3,
ﬁeld strengths62, magnets of different vendors63, and magnets and
implementations by the same vendor64. These comparisons
generally revealed small systematic offsets, suggesting that base-
line and follow-images must always be obtained on the same sys-
tem with identical image parameters; however testeretest errors
were in a similar range between protocols. Ideally, slices should be
orientated perpendicular to the region of interest; in the knee, axial
slices are optimal for imaging the patella, coronal slices for the
(weight-bearing) femorotibial joint; sagittal slices cover all knee
joint surfaces simultaneously but should be sufﬁciently thin to
avoid partial volume effects. Recently, DESS imaging was intro-
duced and cross-calibrated with FLASH for cartilage thickness
measurements65, but is only available from Siemens scanners
(Table I; Fig. 3). The 12-month longitudinal sensitivity to change in
central medial femorotibial joint cartilage thickness was reported
to be0.34 (SRM) for coronal FLASH,0.37 for coronal multiplanar
reconstructed DESS, and 0.36 for sagittal DESS. Using every sec-
ond 0.7 mm slice of the sagittal DESS yielded similar SRMs as using
every slice, and longitudinal correlations of r  0.79 were reported
between the three protocols66. For multicenter trials including
magnets from different vendors, FLASH, SPGR, FFE/WATSc are
therefore recommended, preferably with water excitation. Caution
has to be applied when acquiring these sequences and delayed
gadolinium enhanced MRI of cartilage (dGEMRIC) in the same
session, because lower sensitivity to change in cartilage thickness
has been reported with SPGR in the presence of Gd-DTPA67.
Semi-quantitative grading systems for cartilage and bone
The Whole Organ Magnetic Resonance Imaging Score (WORMS)
is a widely cited semi-quantitative scoring system for knee OA54. It
uses a complex subregional division of the knee rather than lesion-
oriented approach to scoring, especially for cartilage and BMLs. The
BostoneLeeds Osteoarthritis Knee Score (BLOKS) uses a lesion-
oriented approach for BMLs68. Recent studies demonstrated rela-
tive strengths and weaknesses of these scoring systems69,70; to
overcome the latter, the MRI Osteoarthritis Knee Score (MOAKS)59
added subregional assessment, reﬁned the scoring, and removed
redundancies for cartilage and BMLs. While MOAKS is new and
requires further validation, it has been recently used in the OAI71
and in another multicenter trial72 that examines whether arthro-
scopic partial meniscectomy results in better functional outcomes
than non-operative therapy. Relative lack of sensitivity to change is
a potential weakness of semi-quantitative vs quantitative ap-
proaches. Therefore, scoring “within-grade” changes between time
points is now common practice and involves better longitudinal
sensitivity, although requires unblinding to acquisition order73.
Within-grade changes are not part of published scoring systems,
but are clinically relevant, as within-grade changes were shown to
be associated with known OA risk factors and outcomes73. Scoring
within-grade change is particularly important in clinical trials,
since full-grade change may not occur within relatively short
follow-up of <1 year. Yet, a recent systematic review reported semi-
quantitative scoring of cartilage and BMLs to be adequately
responsive, and the pooled SRMs broadly consistent with those for
quantitative cartilage measurement (0.55 for medial tibiofemoralcartilage and 0.43 for BMLs)74. Another systematic review provided
evidence that knee OA pain is cross-sectionally and longitudinally
associated with BMLs75. Semi-quantitative MRI outcomes (i.e.,
changes in cartilage damage and BMLs) have been used in several
clinical trials76e78, and recently strontium ranelate was reported to
reduce the progression of BMLs in the medial femorotibial
compartment79.
Quantitative measurement of cartilage loss
Quantitative measurement of cartilage requires segmentation of
the tissue in joint (compartments)of interest. Theprecisionand inter-
observer reliability for different imaging protocols, orientations, and
segmentation approaches have beenwell documented6,65,74. Various
quantitative metrics can then be extracted (Fig. 3), for which a
nomenclature was proposed by a panel of experts (Fig. 3)80. Face-to-
face comparisons of the precision and sensitivity to change of these
metrics have been presented81,82, and a core set of measures was
identiﬁed, providing independent information on cartilage status
and loss83. This encompassed the total and denuded area of sub-
chondral bone (tAB; dAB), and cartilage thickness (ThC)83 (Fig. 3).
Further, technology has been developed to extract the above metrics
for deﬁned subregions71,81,84. As for JSW loss (see above), some
studies have dichotomized structural progressors from non-
progressors using variable thresholds of cartilage loss, such as pre-
cision85, smallest detectable change (SDC)7, or (subregional) change
in healthy subjects86. With regard to correlation with clinical out-
comes, dABs (Fig. 3), have been associated with concurrent87 and
incident knee pain88. Kneeswith larger rates of femorotibial cartilage
lossweremore likely to subsequently receive knee replacement (KR)
than those with lower rates89,90. A recent caseecontrol study
conﬁrmedsubstantially larger rates of (centralmedial tibial) cartilage
loss in the year prior to KR than in non-replaced controls, indepen-
dent of radiographic status91. The sensitivity to change of cartilage
volume and thickness loss has been reported in a wide range of
studies, covering different cartilagemeasures, cohorts and lengths of
observation7,92e95 (Table II). Predictors of cartilage loss that may be
useful for enriching clinical trials with fast progressors have been
reported; these have included mal-alignment85,96, advanced radio-
graphic OA status (i.e., greater baseline KLG or JSN grade, or smaller
JSW)97e101; frequent pain93,100,102, and high bodyweight/body mass
index (BMI)95,97. Molecular markers were less successful in identi-
fyingprogressors98,103.Meniscus extrusion97,104 alsowas identiﬁed to
predict progression, but requires MRI for recruitment purposes and
was suggested to not increase sensitivity to change81. Further, the
sensitivity was not markedly improved when measurements were
conﬁned to speciﬁc joint regions71,81, albeit central (femorotibial)
subregions displayed somewhat greater rates and sensitivity to
change thanperipheral ones7,99 (Table II). Inperipheral subregions, in
contrast, cartilage thickening was observed, particularly in knees
with early radiographic OA86. In contrast, a non-region speciﬁc (or-
dered value) system of subregion change was identiﬁed to consid-
erably improve the differentiation of cartilage loss between knees
with and without JSN105. Knees with osteophytes but without JSN
displayed rates of change almost indistinguishable from those in
healthy knees (Table II)99. Quantitative measures of cartilage
morphology were used as outcomes of observational trials on ther-
apeutic effects, including non-steroidal anti-inﬂammatory drugs
(NSAIDs)106,107, bisphosphonates108, or glucosamine and chondroitin
sulfate107. They also were used in interventional trials, evaluating
effects of physical exercise109 and joint distraction110, and potential
DMOADs such as celecoxib111, licofelone112, chondroitin sulfate77,
vitamin D supplementation113, strontium ranelate79, and sprifermin
(ﬁbroblast growth factor 18)114. When drug effects on knee cartilage
loss were seen, these were often greater in the lateral than medial
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ment showed less/earlier disease. Quantitative methods were re-
ported to be superior to semi-quantitative ones in assessing the
association between risk factors and cartilage loss85, and structure
modiﬁcation by drug treatment115.
Quantitative measurement of cartilage composition
Different MRI parameters have been proposed as quantitative
markers of cartilage composition and mechanical properties
(Fig. 4), with similar ability to predict compressive moduli at 1.5 T
and 9.4 T116. One is the spinespin (T2) relaxation time derived from
amultiple echo spin echo (MESE) acquisition. Methodological work
suggests that the image with the shortest TE should be eliminated
from T2 computations117, and that T2 offsets exist between coils2. It
is possible to derive T2 and diffusion values from DESS118,119,
creating the potential to measure cartilage composition and
thickness from the same images. T2 is sensitive to collagen matrix
structure and organization in intact cartilage, and has reasonable
reproducibility in multicenter studies120 (intraclass correlation
coefﬁcient (ICC) 0.61e0.98; root mean square coefﬁcient of varia-
tion (RMS CV) 4e14%). Satisfactory precisionwas also reported after
splitting the cartilage layer arbitrarily into two or three horizontal
layers, regions between which collagen orientation varies2.
Although these regions do not perfectly match the superﬁcial,
middle and deep cartilage layers as deﬁned histologically, precise
matching is challenging given limited in-plane resolution. T2 is
considered more useful in morphologically intact cartilage under-
going compositional change and may have limited sensitivity to
change in patients with advanced cartilage defects121.
T1rho relaxation time has been shown to be sensitive to
glycosaminoglycan content122, but has greater precision error than
T2 (ICC 0.20e0.93; RMS CV 4e19%)120. Also, there is disagreement
on the speciﬁcity of T1rho to cartilage glycosaminoglycan123. As a
marker of cartilage glycosaminoglycan, dGEMRIC124 has good
reproducibility (ICC 0.87e0.95)125, and longitudinal change was
found inversely associated with that in cartilage thickness126.
However, dGEMRIC requires intravenous contrast and a 90-min
delay before scanning, making study logistics challenging67. Other
imaging markers of cartilage glycosaminoglycan are Computed
Tomography (CT) after injection of a charged contrast agent into the
knee joint127, sodium MRI128 and chemical exchange saturation
transfer (CEST)129, but precision data on these techniques are
lacking. Sodium MRI requires specialized coils, and sodium and
CEST have greater accuracy at very high ﬁeld strength130, limiting
their applicability. Ultra-short TE imaging has been applied to im-
age the calciﬁed cartilage layer131. In small clinical trials, dGEMRIC
has been shown to be sensitive to weight-loss132 and, in contrast to
T2, has indicated potential treatment effects of oral collagen hy-
drolysate on cartilage composition133.
Quantitative measures of bone
Recent advances in MRI-based analysis of bone have beenmade,
such as semi-(automated) analysis of BMLs134e136, total bone area
and shape137e140, trabecular bone structure134,141,142, and peri-
articular bone structure136,143. Using a DESS MRI sequences, bone
was mapped using >100,000 points per knee140. By applying a
triangulation method, certain bone shape vectors identifying knees
with greater risk of incident knee OA 1 year later compared with
non-incident controls140. Further, change in bone area displayed
greater sensitivity than change in cartilage thickness and radio-
graphic JSW for assessing structural progression139. These methods
have not yet been applied in clinical trials, but may be of particular
interest when anti-resorptive effects on bone are studied108,144.Dual Energy X-ray absorptiometry (DXA) demonstrated greater
bone mineral density (BMD) in knees with greater radiographic OA
severity and speciﬁcally in areas with BMLs143. The latter ﬁnding
was conﬁrmed by quantitative CT, and the medial/lateral BMD ratio
was signiﬁcantly greater in bones with medial BMLs145. CT can
further provide very accurate measures of the density and structure
of subchondral bone in vivo146, but has not been applied in clinical
trials thus far.Direct comparison between radiography and MRI
Meta-analyses suggested a greater sensitivity to change of MRI-
based cartilage loss74 than change in radiographic JSW22, but were
performed on different cohorts. Face-to-face comparison generally
reported greater sensitivity to change of MRI-based cartilage mea-
sures than of radiographic JSW30,93,95,147, but one study found a
somewhat greater SRM for ﬂuoroscopy-based Lyon-Schuss mini-
mum JSW than for cartilage thickness loss in the medial compart-
ment148. The SRM for JSW loss in ﬁxed ﬂexion radiography, in
contrast, was shown tobe substantially less than forMRI in the same
study148 (Table II). The authors proposed that the high responsive-
ness of Lyon-Schuss may be owed to the ﬂuoroscopic guidance
providing a small IMD, and to radiography being performed under
weight-bearing conditions, with diseased cartilage being poten-
tially more compressible than healthy one. Fixed location measures
of JSW have been suggested to partially compensate limitations of
ﬁxed ﬂexion acquisition, with SRMs found similar to those of MRI-
based cartilage loss30. Yet, in a larger sample, greater sensitivity of
MRI-based measures was reported compared with ﬁxed location
JSW over 12 and 24 months31 (Table II). A signiﬁcant relationship
was reported between side differences in radiographic minimum
and ﬁxed location JSW vs percent tibial plateau coverage by the
meniscus (r2z 25%) and central medial femoral cartilage thickness
(r2 z 50%)24. Other meniscus measures and cartilage regions
showed weaker associations. Including only knees with reasonable
alignment between the tibial plateau and the X-ray beam improved
the correlation with femoral cartilage thickness (r2z 65%), but not
with meniscus coverage, suggesting that JSW provides a better
representation of (central) femoral cartilage thickness when satis-
factory radiographic positioning is achieved24. Initial studies found
only weak correlations between longitudinal cartilage loss in MRI
and JSW loss in radiography93,149,150. However, stronger correlations
were observed when minimum (or central ﬁxed location) JSW
changewas comparedwith cartilage loss in the central aspect of the
medial femorotibial compartment31,79,97. MRI was found superior to
radiography in differentiating rates of cartilage loss in knees with
advanced vs early radiographic OA105, and a very small study re-
ported superiority of MRI in predicting knee replacement relative to
JSW change from extended radiographs149. Also, interventional
studies indicated that drug effects may be more efﬁciently detected
using MRI-based cartilage loss than radiography107,112Recommendations and summary
General
 Imaging biomarkers used in clinical trials should be precise and
take into account the speciﬁc mechanism of DMOAD action
thereby lying on the therapeutic pathway.
 Tissues and joint regions of interest should be imaged with full
anatomical coverage and adequate image orientation.
 All hardware and image settings must be kept constant between
baseline and follow-up, to avoid systematic offsets biasing
assessment of longitudinal change.
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rants consistency and sensitivity to change.
 Power calculations should take into account the potential
magnitude of DMOAD effects as well as reported sensitivity to
change for various selection criteria and design parameters.Radiography
 Standards of knee positioning (weight-bearing and ﬁxed
ﬂexion) are important.
 Each of both knees should be imaged separately to ensure
minimal X-ray beam divergence.
 The X-ray beam must be aligned with the medial tibial plateau;
the IMD should be 1.0 mm.
 Several modiﬁcations of radiographic classiﬁcation systems
exist, these should therefore be clearly deﬁned and
documented.
 In ﬁxed ﬂexion radiographs of OA knees, central ﬁxed location
JSW measurements may be more responsive than that of min-
imum JSW.MRI
 Imaging should be performed at 1.5 T, using dedicated (knee)
coils.
 Fluid-sensitive MR images in 2e3 orthogonal planes are suited
for assessing focal cartilage defects, and fat-suppressed images
for BMLs.
 Scoring “within-grade” changes of semi-quantitative MRI scores
between time points involves better longitudinal sensitivity, but
requires unblinding to acquisition order.
 Fat-suppressed or water excitation T1-weighted gradient-echo
or DESS images with 1.5 mm a slice thickness of and
0.35 mm in-plane resolution are suited for cartilage thickness
analysis.
 T2 should be derived from multiple (6e7) echoes. Superﬁcial
and deep cartilage layers should be assessed separately, because
collagen orientation varies. However, T2 may have limited
responsiveness in patients with advanced cartilage defects.
 Other techniques for measuring cartilage composition and bone
shape/structure are available and should be further evaluated in
clinical trials.
When the above recommendations are taken into account,
current imaging methodologies provide powerful tools for scoring
and measuring morphological and compositional aspects of artic-
ular tissues, capturing longitudinal change with reasonable to
excellent sensitivity. Under these conditions, imaging has tremen-
dous potential for ascertaining treatment effects on various joint
structures, potentially over shorter time scales than required for
demonstrating effects on clinical outcomes.Contributions
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